Hims & Hers Health has sold off ~40% GLP-1 turbulence, but the core growth story remains intact. Read why HIMS stock is a ...

For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...

Even so, in an interview with The Economist, Mr Doustdar sounded confident that Novo can recover. His prescription is to push ...

HIMS grows its telehealth-to-prescription model with new offerings in weight loss, hormone care and diagnostics.

As competitive as the obesity drug market has become, Novo Nordisk's decision to slash the prices of its GLP-1 agonist drugs could put it back on the right track. While profit margins may slip due to ...

Novo Nordisk enters the final stretch of 2025 looking almost unrecognizable from the market darling it was just months ago.

The dramatic stock slump, which puts Novo Nordisk at a historically cheap valuation, reflects investor concern over future sales growth and competition, particularly from rival Eli Lilly & Co.

For a 45-year-old who pays out of pocket for Wegovy, the cost comes to $3,900 a year - even with the discounts. For a Medicare beneficiary, that cost will be $600 a year in copays. But some research ...

The coming year, 2026, is shaping up as a critical operational and financial test. A head-to-head comparative study between Novo Nordisk's CagriSema and Eli Lilly's Zepbound, scheduled for 2026, will ...

Online telehealth company Hims and Hers Health is launching its weight-loss membership and treatment plans in the United ...

Shares of Hims & Hers are trending Thursday morning. The San Francisco-based telehealth company announced an international ...